参考文献/References:
[1] Goldblatt F, Neill SGO. Clinical aspects of autoimmune rheumatic diseases[J]. Lancet,2013,382(9894):797-808.
[2] Hollan I, Luigi P, Ahearn JM,et al. Autoimmunity reviews cardiovascular disease in autoimmune rheumatic diseases[J]. Autoimmun Rev,2013,12(10):1004-1015.
[3] Symmons DPM, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE[J]. Nat Publ Gr,2011,7(7):399-408.
[4] Thavendiranathan P, Walls M, Giri S, et al. Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping[J]. Circ Cardiovasc Imaging, 2012,(5):102-110.
[5] Taylor AJ, Salerno M, Dharmakumar R,et al. T1 mapping basic techniques and clinical applications[J]. JACC: Cardiovascular Imaging 2016,9(1):67-81.
[6] Nadjiri J, Nieberler H, Hendrich E, et al. Performance of native and contrast-enhanced T1 mapping to detect myocardial damage in patients with suspected myocarditis?: a head-to-head comparison of diferent cardiovascular magnetic resonance techniques[J]. Int J Cardiovasc Imaging,2016,33(4):539-547.
[7] Soltész P, Kerekes G, Dér H,et al. Autoimmunity Reviews Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment[J]. Autoimmun Rev,2011,10(7):416-425.
[8] Cohen Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides[J]. Best Pract Res Clin Rheumatol,2013,27(1):33-44.
[9] Arida A, Protogerou AD, Kitas GD, et al. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases[J].Int J Mol Sci,2018,19(7):1-27.
[10] Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus[J]. Arthritis Rheum,2001,44(10):2331-2337.
[11] Chico-calero I, Barreiro O, Lo E, et al. CD69 limits the severity of cardiomyopathy after autoimmune myocarditis[J]. Circulation,2010,122(14):1396-1404.
[12] Machino-ohtsuka T, Tajiri K, Kimura T,et al. Tenascin-C aggravates autoimmune myocarditis via dendritic cell activation and Th17 cell differentiation[J]. J Am Heart Assoc, 2014,3(6):e001052.
[13] Weber KT, Sun Y, Bhattacharya SK, et al. Myofibroblast-mediated mechanisms of pathological remodelling of the heart[J]. Nat Rev Cardiol,2013,10(1):15-26.
[14] Mavrogeni SI, Kitas GD, Dimitroulas T,et al. Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use[J].Int J Cardiol, 2016 ,217:135-148.
[15] Ristic AD, Maksimovic R, Simeunovic DS, et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases[J]. Rheumatology, 2006,45 Suppl(4):39-42.
[16] Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension[J]. Chest,2013,144(4):1346-1356.
[17] Mayr A, Kitterer D, Latus J, et al. Evaluation of myocardial involvement in patients with connective tissue disorders: a multi-parametric cardiovascular magnetic resonance study[J]. J Cardiovasc Magn Reson,2016,18(1):67.
[18] Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision[J]. J Cardiovasc Magn Reson, 2014,16:2.
[19] Seneviratne MG, Grieve SM, Figtree GA, et al. Prevalence, distribution and clinical correlates of myocardial fibrosis in systemic lupus erythematosus: a cardiac magnetic resonance study[J]. Lupus,2016,25(6):573-581.
[20] Mavrogeni S, Servos G,Smerla R,,et al. Cardiovascularinvolvement inpediatricsystemicautoimmune diseases: the emerging role of noninvasivecardiovascularimaging[J]. Inflamm Allergy Drug Targets,2015,13(6):371-381.
[21] Ishimori ML, Martin R, Berman DS, et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus rrythematosus[J]. JACC Cardiovasc Imaging,2011,4(1):27-33.
[22] Chowienczyk P, Nagel E, Botnar RM,et al. Coronary vessel wall contrast enhancement imaging as a potential direct marker of coronary involvement[J]. JACC Cardiovascular Imaging,2014,7(8):762-770.
[23] Puntmann VO, D’Cruz D, Smith Z,et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus[J]. Circ Cardiovasc Imaging,2013,6(2):295-301.
[24] Hinojar R, Foote L, Sangle S, et al. Native T1 and T2 mapping by CMR in lupus myocarditis?: Disease recognition and response to treatment[J]. Int J Cardiol,2016,222:717-726.
[25] Sano M, Satoh H, Suwa K, et. Characteristics and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis[J]. Heart Vessels, 2015,30(6):779-788.
[26] Mcglinchey EL, Oyesiku L, Diaz KM, et al. Left ventricle replacement fibrosis detected by CMR associated with cardiovascular events in systemic sclerosis patients[J].J Am Coll Cardial,2018,71(6):703-705.
[27] Gyllenhammar T, Kanski M, Engblom H, et al. Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study[J].BMC Cardiovasc Disord,2018,18(1):16.
[28] Barison A, Gargani L, de Marchi D , et al. Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance[J]. Eur Heart J Cardiovascu Imaging,2015,16(1);74-80.
[29] Kobayashi Y, Kobayashi H, Giles JT, et al. Detection of left ventricular regional dysfunction and myocardial abnormalities using complementary cardiac magnetic resonance imaging in patients with systemic sclerosis without cardiac symptoms: a pilot study[J]. Intern Med,2016,55(3):237-243.
[30] Greulich S, Mayr A, Kitterer D,et al. Advanced myocardial tissue characterisation by a multi-component CMR protocol in patients with rheumatoid arthritis[J]. Eur Radiol,2017;27(11):4639-4649.
[31] Ferreira VM, Hil DP, Matthews PM, et al. Diffuse myocardial fibrosis and infl ammation in rheumatoid arthritis[J]. JACC Cardiovasc imaging, 2015;8(5):526-536.
[32] Mavrogeni S, Douskou M, Manoussakis MN. Contrast-enhanced CMR imaging reveals myocardial involvement in idiopathic inflammatory myopathy without cardiac manifestations[J]. JACC Cardiovasc Imaging,2011,4(12):1324-1325.
[33] Yu L, Sun J, Sun J, et al. Early Detection of myocardial involvement by T1 mapping of cardiac MRI in idiopathic inflammatory myopathy[J]. J Magn Reson Imaging, 2018,40(8):415-422.
[34] Huber AT, Bravetti M, Lamy J, et al. Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping[J]. J Cardiovasc Magn Reson,2018,20(1):11.
[35] Mavrogeni S, Dimitroulas T. The role of multimodality imaging in the evaluation of takayasu arteritis[J]. Semin Arthritis Rheum,2013,42(4):401-412.
[36] Mavrogeni S, Bratis K, Karanasios E, et al. CMR evaluation of cardiac involvement during the convalescence of kawasaki disease prosthetic heart valve ring thrombosis[J]. JACC Cardiovasc Imaging,2011,4(10):1140-1141.
[37] Hazebroek MR, Kemna MJ, Schalla S, et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: Eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis[J]. Int J Cardiol,2015,199:170-179.
[38] Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis[J]. Circulation,2009,120(20):1969-1977.
[39] Murtagh G, Laffin LJ, Beshai JF, et al. Cardiomyopathies prognosis of myocardial damage in sarcoidosis patients[J]. Cir Cardiovasc Imaging,2016,9(1):e003738.
[40] Puntmann VO,Isted A,Hinojar R,et al. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis[J]. Radiology,2017,285(1):63-72.
相似文献/References:
[1]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[2]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[3]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[4]冯泽豪 姜萌 卜军.心脏磁共振评价化疗所致心肌损伤的研究进展[J].心血管病学进展,2019,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
FENG Zehao,JIANG Meng,PU Jun.Cardiovascular Magnetic Resonance for Detection of Myocardial Impairments Caused by Chemotherapy[J].Advances in Cardiovascular Diseases,2019,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
[5]金荣杰 徐勇 邓珏琳 沈明志.应用心脏磁共振评估前列地尔对ST段抬高型心肌梗死患者心肌灌注的影响[J].心血管病学进展,2020,(10):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
JIN RongjieXU YongDENG JuelinSHEN Mingzhi.Effect of Alprostadil on Myocardial Perfusion of Patients with ST Segment Elevation Myocardial Infarction Directly Receiving Percutaneous Coronary Intervention Assessed with Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(5):1096.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.023]
[6]张宁 王嫱.心脏磁共振评估特发性炎症性肌病患者心脏受累的研究进展[J].心血管病学进展,2020,(11):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
ZHANG Ning,WANG Qiang.Advances in Evaluating Cardiac Involvement in Idiopathic Inflammatory Myopathy by Cardiac Magnetic Resonance[J].Advances in Cardiovascular Diseases,2020,(5):1145.[doi:10.16806/j.cnki.issn.1004-3934.20.11.000]
[7]陈小玲 陈玉成.肺高压心肌纤维化磁共振评价及临床意义[J].心血管病学进展,2021,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
CHEN Xiaoling,CHEN Yucheng.Cardiac Magnetic Resonance Evaluation and the Clinical Value of Myocardial Fibrosis in Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2021,(5):135.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.010]
[8]尹丽丹 蒲守芳 何娟 陈玉成.右心室评价方法及其临床应用[J].心血管病学进展,2021,(6):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]
YIN Lidan,PU Shoufang,HE Juan,et al.The Methods to Evaluation of Right Ventricular and its Clinical Application[J].Advances in Cardiovascular Diseases,2021,(5):521.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.011]
[9]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(5):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[10]蒲华霞 彭礼清.系统性红斑狼疮心脏受累的MRI评价进展[J].心血管病学进展,2021,(8):716.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.011]
PU huaxia,PENG Liqing.Magnetic Resonance Imaging in the Evaluation of Cardiac Involvement in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2021,(5):716.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.011]